

REFERENCES

- Abe, K., Suzuki, T., Ijiri, M., Koyama, Y., Isemura, M., and Kinae, N. (2007). The anti-fibrotic effect of green tea with a high catechin content in the galactosamine-injured rat liver. *Biomed Res (Tokyo, Japan)* 28, 43-48.
- Aisen, P., Enns, C., and Wessling-Resnick, M. (2001). Chemistry and biology of eukaryotic iron metabolism. *Int J Biochem Cell Biol* 33, 940-959.
- Aldouri, M.A., Wonke, B., Hoffbrand, A.V., Flynn, D.M., Laulich, M., Fenton, L.A., Scheuer, P.J., Kibbler, C.C., Allwood, C.A., Brown, D., *et al.* (1987). Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine. *J Clin Pathol* 40, 1353-1359.
- Andrews, N.C. (1999). Disorders of iron metabolism. *N Engl J Med* 341, 1986-1995.
- Anghileri, L.J., and Thouvenot, P. (2000). Natural polyphenols-iron interaction: its biological importance. *Biol Trace Elem Res* 73, 251-258.
- Arezzini, B., Lunghi, B., Lungarella, G., and Gardi, C. (2003). Iron overload enhances the development of experimental liver cirrhosis in mice. *Int J Biochem Cell Biology* 35, 486-495.
- Arthur, M.J. (1996). Iron overload and liver fibrosis. *J Gastroenterol Hepatol* 11, 1124-1129.
- Asare, G.A., Mossanda, K.S., Kew, M.C., Paterson, A.C., Kahler-Venter, C.P., and Siziba, K. (2006). Hepatocellular carcinoma caused by iron overload: a possible mechanism of direct hepatocarcinogenicity. *Toxicol* 219, 41-52.
- Ausar, S.F., Morcillo, M., Leon, A.E., Ribotta, P.D., Masih, R., Vilaro Mainero, M., Amigone, J.L., Rubin, G., Lescano, C., Castagna, L.F., *et al.* (2003). Improvement of HDL- and LDL-cholesterol levels in diabetic subjects by feeding bread containing chitosan. *J Med Food* 6, 397-399.
- Baltaziak, M., Skrzydlewska, E., Sulik, A., Famulski, W., and Koda, M. (2004). Green tea as an antioxidant which protects against alcohol induced injury in rats -- a histopathological examination. *Folia Morphologica* 63, 123-126.
- Barisani, D., Berg, C.L., Wessling-Resnick, M., and Gollan, J.L. (1995). Evidence for a low Km transporter for non-transferrin-bound iron in isolated rat hepatocytes. *Am J Physiol* 269, G570-576.

- Barman Balfour, J.A., and Foster, R.H. (1999). Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. *Drugs* 58, 553-578.
- Benz, E.J., Jr. (1980). Hemoglobin switching in animals. *Texas Reports on Biology and Medicine* 40, 111-123.
- Beutler, E., Hoffbrand, A.V., and Cook, J.D. (2003). Iron deficiency and overload. *Hematological / Education Program of the American Society of Hematology American Society of Hematology*, 40-61.
- Bhavnani, M., Lloyd, D., Bhattacharyya, A., Marples, J., Elton, P., and Worwood, M. (2000). Screening for genetic haemochromatosis in blood samples with raised alanine aminotransferase. *Gut* 46, 707-710.
- Biswas, S., Bhattacharyya, J., and Dutta, A.G. (2005). Oxidant induced injury of erythrocyte-role of green tea leaf and ascorbic acid. *Mol Cell Biochem* 276, 205-210.
- Bondiolotti, G., Bareggi, S.R., Frega, N.G., Strabioli, S., and Cornelli, U. (2007). Activity of two different polyglucosamines, L112 and FF45, on body weight in male rats. *Eur J Pharmacol* 567, 155-158.
- Bonkovsky, H.L. (1991). Iron and the liver. *Am J Med Sci* 301, 32-43.
- Bose, M., Lambert, J.D., Ju, J., Reuhl, K.R., Shapses, S.A., and Yang, C.S. (2008). The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. *J Nutri* 138, 1677-1683.
- Breuer, W., Ronson, A., Slotki, I.N., Abramov, A., Hershko, C., and Cabantchik, Z.I. (2000). The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. *Blood* 95, 2975-2982.
- Brittenham, G.M. (2003). Iron chelators and iron toxicity. *Alcohol* 30, 151-158.
- Britton, R.S., Leicester, K.L., and Bacon, B.R. (2002). Iron toxicity and chelation therapy. *Int J Hematol* 76, 219-228.
- Bucolo, G., and David, H. (1973). Quantitative determination of serum triglycerides by the use of enzymes. *Clin Chem* 19, 476-482.
- Cabantchik, Z.I., Breuer, W., Zanninelli, G., and Cianciulli, P. (2005). LPI-labile plasma iron in iron overload. *Best Pract Res Clin Haematol* 18, 277-287.

- Canbakan, B., Senturk, H., Tahan, V., Hatemi, I., Balci, H., Toptas, T., Sonsuz, A., Velet, M., Aydin, S., Dirican, A., *et al.* (2007). Clinical, biochemical and histological correlations in a group of non-drinker subjects with non-alcoholic fatty liver disease. *Acta Gastro-enterologica Belgica* 70, 277-284.
- Cappellini, M.D. (2008). Long-term efficacy and safety of deferasirox. *Blood Reviews* 22 *Suppl* 2, S35-41.
- Cappellini, M.D., Cohen, A., Piga, A., Bejaoui, M., Perrotta, S., Agaoglu, L., Aydinok, Y., Kattamis, A., Kilinc, Y., Porter, J., *et al.* (2006). A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. *Blood* 107, 3455-3462.
- Cappellini, M.D., and Piga, A. (2008). Current status in iron chelation in hemoglobinopathies. *Curr Mol Med* 8, 663-674.
- Chanadiri, T.V., Esaiashvili, M.V., and Chkhikvishvili, I.D. (2006). [Disorders of liver oxidative metabolism during experimental obesity]. *Georgian Med News*, 85-87.
- Chen, Z., Zhu, Q.Y., Tsang, D., and Huang, Y. (2001). Degradation of green tea catechins in tea drinks. *J Agric Food Chem* 49, 477-482.
- Chirico, S. (1994). High-performance liquid chromatography-based thiobarbituric acid tests. *Methods Enzymol* 233, 314-318.
- Crespy, V., and Williamson, G. (2004). A review of the health effects of green tea catechins in in vivo animal models. *J Nutr* 134, 3431S-3440S.
- Dai, F., Miao, Q., Zhou, B., Yang, L., and Liu, Z.L. (2006). Protective effects of flavonols and their glycosides against free radical-induced oxidative hemolysis of red blood cells. *Life Sci* 78, 2488-2493.
- Emerit, J., Beaumont, C., and Trivin, F. (2001). Iron metabolism, free radicals, and oxidative injury. *Biomed Pharmacother* 55, 333-339.
- Fiorelli, G., Fargion, S., Piperno, A., Battafarano, N., and Cappellini, M.D. (1990). Iron metabolism in thalassemia intermedia. *Haematologica* 75 *Suppl* 5, 89-95.
- Fiorini, R.N., Donovan, J.L., Rodwell, D., Evans, Z., Cheng, G., May, H.D., Milliken, C.E., Markowitz, J.S., Campbell, C., Haines, J.K., *et al.* (2005). Short-term administration of (-)-epigallocatechin gallate reduces hepatic steatosis and protects

- against warm hepatic ischemia/reperfusion injury in steatotic mice. *Liver Transpl* *11*, 298-308.
- Fischer, R., Piga, A., Harmatz, P., and Nielsen, P. (2005). Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. *Ann NY Acad Sci* *1054*, 350-357.
- Fletcher, L.M., Bridle, K.R., and Crawford, D.H. (2003). Effect of alcohol on iron storage diseases of the liver. *Best Practice & Research* *17*, 663-677.
- Friedman, S.L. (1999). Stellate cell activation in alcoholic fibrosis--an overview. *Alcoholism, Clin Expt Res* *23*, 904-910.
- Garrick, L.M., Dolan, K.G., Romano, M.A., and Garrick, M.D. (1999). Non-transferrin-bound iron uptake in Belgrade and normal rat erythroid cells. *J Cell Physiol* *178*, 349-358.
- George, D.K., Goldwurm, S., MacDonald, G.A., Cowley, L.L., Walker, N.I., Ward, P.J., Jazwinska, E.C., and Powell, L.W. (1998). Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. *Gastroenterol* *114*, 311-318.
- Glickstein, H., El, R.B., Shvartsman, M., and Cabantchik, Z.I. (2005). Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. *Blood* *106*, 3242-3250.
- Grundy, M.A., Gorman, N., Sinclair, P.R., Chorney, M.J., and Gerhard, G.S. (2004). High-throughput non-heme iron assay for animal tissues. *J Biochem Biophys Methods* *59*, 195-200.
- Gutteridge, J.M., Rowley, D.A., and Halliwell, B. (1982). Superoxide-dependent formation of hydroxyl radicals and lipid peroxidation in the presence of iron salts. Detection of 'catalytic' iron and anti-oxidant activity in extracellular fluids. *Biochem J* *206*, 605-609.
- Halder, J., and Bhaduri, A.N. (1998). Protective role of black tea against oxidative damage of human red blood cells. *Biochem Biophys Res Commun* *244*, 903-907.
- Han, D.W., Park, Y.H., Kim, J.K., Lee, K.Y., Hyon, S.H., Suh, H., and Park, J.C. (2004). Effects of green tea polyphenol on preservation of human saphenous vein. *J Biotechnol* *110*, 109-117.

- Han, L.K., Kimura, Y., and Okuda, H. (1999). Reduction in fat storage during chitin-chitosan treatment in mice fed a high-fat diet. *Int J Obes Relat Metab Disord* 23, 174-179.
- Harrison, P.M., and Arosio, P. (1996). The ferritins: molecular properties, iron storage function and cellular regulation. *Biochim Biophys Acta* 1275, 161-203.
- Hershko, C. (2006). Oral iron chelators: new opportunities and new dilemmas. *Haematologica* 91, 1307-1312.
- Hershko, C.M., Link, G.M., Konijn, A.M., and Cabantchik, Z.I. (2005). Iron chelation therapy. *Curr Hematol Rep* 4, 110-116.
- Hider, R.C., Kontoghiorghes, G.J., and Siver, J. (1982).
- Higashi, N., Kohjima, M., Fukushima, M., Ohta, S., Kotoh, K., Enjoji, M., Kobayashi, N., and Nakamuta, M. (2005). Epigallocatechin-3-gallate, a green-tea polyphenol, suppresses Rho signaling in TWNT-4 human hepatic stellate cells. *J Lab Clin Med* 145, 316-322.
- Higdon, J.V., and Frei, B. (2003). Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. *Crit Rev Food Sci Nutr* 43, 89-143.
- Hirano S, S.H., Akiyama Y. (1990). Chitosan: a biocompatible material for oral and intravenous administration. . *Progress in Biomedical Polymers*, Plenum, New York, In C G Gebelein and R L Dunn (eds),, 283–289.
- Hoffbrand, A.V., Cohen, A., and Hershko, C. (2003). Role of deferiprone in chelation therapy for transfusional iron overload. *Blood* 102, 17-24.
- Hossain, S., Rahman, A., Kabir, Y., Shams, A.A., Afros, F., and Hashimoto, M. (2007). Effects of shrimp (*Macrobracium rosenbergii*)-derived chitosan on plasma lipid profile and liver lipid peroxide levels in normo- and hypercholesterolaemic rats. *Clin Expt Pharmacol Physiol* 34, 170-176.
- Hsiao, T.J., Chen, J.C., and Wang, J.D. (2004). Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. *Int J Obes Relat Metab Disord* 28, 167-172.
- Huo, Y., McConnell, S.C., Liu, S.R., Yang, R., Zhang, T.T., Sun, C.W., Wu, L.C., and Ryan, T.M. (2009). Humanized Mouse Model of Cooley's Anemia. *J Biol Chem* 284, 4889-4896.

- Imbert-Bismut, F., Charlotte, F., Turlin, B., Khalil, L., Piton, A., Brissot, P., Le Charpentier, Y., Delattre, J., Opolon, P., Deugnier, Y., *et al.* (1999). Low hepatic iron concentration: evaluation of two complementary methods, colorimetric assay and iron histological scoring. *J Clin Pathol* 52, 430-434.
- Incharoen, T., Thephinlap, C., Srichairatanakool, S., Chattipakorn, S., Winichagoon, P., Fucharoen, S., Vadolas, J., Chattipakorn, N. (2007). Heart rate variability in β -thalassemic mice. *Int J Cardiol* 121, 203-204.
- Jamsai, D., Zaibak, F., Khongnium, W., Vadolas, J., Voullaire, L., Fowler, K.J., Gazeas, S., Fucharoen, S., Williamson, R., Ioannou, P.A. (2005). A humanized mouse model for a common β 0-thalassemia mutation. *Genomics* 85, 453-461.
- Jamsai, D., Zaibak, F., Vadolas, J., Voullaire, L., Fowler, K.J., Gazeas, S., Peters, H., Fucharoen, S., Williamson, R., Ioannou, P.A. (2006). A humanized BAC transgenic/knockout mouse model for HbE/ β -thalassemia. *Genomics* 88, 309-315.
- Jennings, C.D., Boleyn, K., Bridges, S.R., Wood, P.J., and Anderson, J.W. (1988). A comparison of the lipid-lowering and intestinal morphological effects of cholestyramine, chitosan, and oat gum in rats. *Proc Soc Expt Biol Med Soc Expt Biol Med (New York, NY)* 189, 13-20.
- Jin, X., Zheng, R.H., and Li, Y.M. (2008). Green tea consumption and liver disease: a systematic review. *Liver Int* 28, 990-996.
- Kakhlon, O., and Cabantchik, Z.I. (2002). The labile iron pool: characterization, measurement, and participation in cellular processes(1). *Free Radic Biol Med* 33, 1037-1046.
- Kanauchi, O., Deuchi, K., Imasato, Y., Shizukuishi, M., and Kobayashi, E. (1995). Mechanism for the inhibition of fat digestion by chitosan and for the synergistic effect of ascorbate. *Biosci, Biotechnol, and Biochem* 59, 786-790.
- Kirsch, R., Clarkson, V., Shephard, E.G., Marais, D.A., Jaffer, M.A., Woodburne, V.E., Kirsch, R.E., and Hall Pde, L. (2003). Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. *J Gastroenterol Hepatol* 18, 1272-1282.
- Kushner, J.P., Porter, J.P., and Olivieri, N.F. (2001). Secondary iron overload. *Hematology Am Soc Hematol Educ Program*, 47-61.

- Lau, K.M., He, Z.D., Dong, H., Fung, K.P., and But, P.P. (2002). Anti-oxidative, anti-inflammatory and hepato-protective effects of *Ligustrum robustum*. *J Ethnopharmacol* 83, 63-71.
- Liuzzi, J.P., Aydemir, F., Nam, H., Knutson, M.D., and Cousins, R.J. (2006). Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. *Proc Nat Acad Sci USA* 103, 13612-13617.
- Lykkesfeldt, J., Morgan, E., Christen, S., Skovgaard, L.T., and Moos, T. (2007). Oxidative stress and damage in liver, but not in brain, of Fischer 344 rats subjected to dietary iron supplementation with lipid-soluble [(3,5,5-trimethylhexanoyl)ferrocene]. *J Biochem Mol Toxicol* 21, 145-155.
- Mandel, S., Amit, T., Reznichenko, L., Weinreb, O., and Youdim, M.B. (2006). Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. *Mol Nutr Food Res* 50, 229-234.
- Mascitelli, L., Pezzetta, F., and Sullivan, J.L. (2006). Iron chelation by green tea flavonoids and improved endothelial function in chronic smokers. *Circ J* 70, 1523; author reply 1523-1524.
- Megraw, R.E., Dunn, D.E., and Biggs, H.G. (1979). Manual and continuous-flow colorimetry of triacylglycerols by a fully enzymic method. *Clin Chem* 25, 273-278.
- Meo, A., Ruggeri, A., La Rosa, M.A., Zanghi, L., Morabito, N., and Duca, L. (2006). Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation. *Hemoglobin* 30, 131-137.
- Messner, D.J., and Kowdley, K.V. (2008). Neoplastic transformation of rat liver epithelial cells is enhanced by non-transferrin-bound iron. *BMC Gastroenterol* 8, 2.
- Mhurchu, C.N., Poppitt, S.D., McGill, A.T., Leahy, F.E., Bennett, D.A., Lin, R.B., Ormrod, D., Ward, L., Strik, C., and Rodgers, A. (2004). The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. *Int J Obes Relat Metab Disord* 28, 1149-1156.
- Muzzarelli, R.A., Ilari, P., and Petrarulo, M. (1994). Solubility and structure of N-carboxymethylchitosan. *Int J Biol Macromol* 16, 177-180.

- Nakamuta, M., Higashi, N., Kohjima, M., Fukushima, M., Ohta, S., Kotoh, K., Kobayashi, N., and Enjoji, M. (2005). Epigallocatechin-3-gallate, a polyphenol component of green tea, suppresses both collagen production and collagenase activity in hepatic stellate cells. *Int J Mol Med* 16, 677-681.
- Nelson, S.K., and McCord, J.M. (1998). Iron, oxygen radicals, and disease. *Adv Mol Cell Biol* 25, 157-183.
- Nielsen, P., Fischer, R., Engelhardt, R., Tondury, P., Gabbe, E.E., and Janka, G.E. (1995). Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone. *Br J Haematol* 91, 827-833.
- Nisbet-Brown, E., Olivieri, N.F., Giardina, P.J., Grady, R.W., Neufeld, E.J., Sechaud, R., Krebs-Brown, A.J., Anderson, J.R., Alberti, D., Sizer, K.C., *et al.* (2003). Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. *Lancet* 361, 1597-1602.
- Olivieri, N.F., Brittenham, G.M., McLaren, C.E., Templeton, D.M., Cameron, R.G., McClelland, R.A., Burt, A.D., and Fleming, K.A. (1998). Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. *N Engl J Med* 339, 417-423.
- Oudit, G.Y., Sun, H., Trivieri, M.G., Koch, S.E., Dawood, F., Ackerley, C., Yazdanpanah, M., Wilson, G.J., Schwartz, A., Liu, P.P., *et al.* (2003). L-type Ca²⁺ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. *Nature Med* 9, 1187-1194.
- Oudit, G.Y., Trivieri, M.G., Khaper, N., Liu, P.P., and Backx, P.H. (2006). Role of L-type Ca²⁺ channels in iron transport and iron-overload cardiomyopathy. *J Mol Med (Berlin, Germany)* 84, 349-364.
- Ounjaijean, S. (2004). Iron-chelating property of green tea extract in iron-overload status. In *Biochemistry (Chiang Mai, Chiang Mai University)*, pp. 1-157.
- Ounjaijean, S., Thephinlap, C., Khansuwan, U., Phisalapong, C., Fucharoen, S., Porter, J.B., and Srichairatanakool, S. (2008). Effect of green tea on iron status and oxidative stress in iron-loaded rats. *Med Chem* 4, 365-370.
- Papanikolaou, G., and Pantopoulos, K. (2005). Iron metabolism and toxicity. *Toxicol Appl Pharmacol* 202, 199-211.

- Pietrangelo, A. (2002). Mechanism of iron toxicity. *Adv Exp Med Biol* 509, 19-43.
- Pootrakul, P., Breuer, W., Sametband, M., Sirankapracha, P., Hershko, C., and Cabantchik, Z.I. (2004). Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. *Blood* 104, 1504-1510.
- Pootrakul, P., Vongsmasa, V., La-onphanich, P., and Wasi, P. (1981). Serum ferritin levels in thalassemias and the effect of splenectomy. *Acta Haematologica* 66, 244-250.
- Porter, J.B. (1997). A risk-benefit assessment of iron-chelation therapy. *Drug Saf* 17, 407-421.
- Porter, J.B. (2001). Deferoxamine pharmacokinetics. *Semin Hematol* 38, 63-68.
- Porter, J.B., Rafique, R., Srichairatanakool, S., Davis, B.A., Shah, F.T., Hair, T., and Evans, P. (2005). Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use. *Ann NY Acad Sci* 1054, 155-168.
- Randell, E.W., Parkes, J.G., Olivieri, N.F., and Templeton, D.M. (1994). Uptake of non-transferrin-bound iron by both reductive and nonreductive processes is modulated by intracellular iron. *J Biol Chem* 269, 16046-16053.
- Reitman, S., and Frankel, S. (1957). A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. *Am J Clin Pathol* 28, 56-63.
- Richardson, D.R., and Ponka, P. (1997). The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. *Biochim Biophys Acta* 1331, 1-40.
- Richmond, W. (1973). Preparation and properties of a cholesterol oxidase from *Nocardia* sp. and its application to the enzymatic assay of total cholesterol in serum. *Clin Chem* 19, 1350-1356.
- Rund, D., and Rachmilewitz, E. (2000). New trends in the treatment of beta-thalassemia. *Crit Rev Oncol Hematol* 33, 105-118.
- Ryan, P., and Hynes, M.J. (2007). The kinetics and mechanisms of the complex formation and antioxidant behaviour of the polyphenols EGCg and ECG with iron(III). *J Inorg Biochem* 101, 585-593.

- Scott, M.D., and Eaton, J.W. (1995). Thalassaemic erythrocytes: cellular suicide arising from iron and glutathione-dependent oxidation reactions? *Br J Haematol* *91*, 811-819.
- Shigematsu, N., Asano, R., Shimosaka, M., and Okazaki, M. (2001). Effect of long term-administration with *Gymnema sylvestre* R. BR on plasma and liver lipid in rats. *Biol Pharmaceutical Bulletin* *24*, 643-649.
- Siah, C.W., Trinder, D., and Olynyk, J.K. (2005). Iron overload. *Clin Chim Acta* *358*, 24-36.
- Srichairatanakool, S., Ounjaijean, S., Thephinlap, C., Khansuwan, U., Phisalpong, C., and Fucharoen, S. (2006). Iron-chelating and free-radical scavenging activities of microwave-processed green tea in iron overload. *Hemoglobin* *30*, 311-327.
- St Pierre, T.G., Clark, P.R., Chua-anusorn, W., Fleming, A.J., Jeffrey, G.P., Olynyk, J.K., Potrakul, P., Robins, E., and Lindeman, R. (2005). Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. *Blood* *105*, 855-861.
- Stal, P., Broome, U., Scheynius, A., Befrits, R., and Hulcrantz, R. (1995). Kupffer cell iron overload induces intercellular adhesion molecule-1 expression on hepatocytes in genetic hemochromatosis. *Hepatology (Baltimore, Md)* *21*, 1308-1316.
- Sumida, Y., Yoshikawa, T., and Okanoue, T. (2009). Role of hepatic iron in non-alcoholic steatohepatitis. *Hepatology Res* *39*, 213-222.
- Sumiyoshi, M., and Kimura, Y. (2006). Low molecular weight chitosan inhibits obesity induced by feeding a high-fat diet long-term in mice. *J Pharmacy Pharmacol* *58*, 201-207.
- Thakerngpol, K., Sonakul, D., Fucharoen, S., Vathanopas, V., and Stitnimankarn, T. (1988). Histochemical study of liver tissue from thalassemic patients. *Birth Defects Original Article Series* *23*, 193-198.
- Thephinlap, C., Ounjaijean, S., Khansuwan, U., Fucharoen, S., Porter, J.B., and Srichairatanakool, S. (2007). Epigallocatechin-3-gallate and epicatechin-3-gallate from green tea decrease plasma non-transferrin bound iron and erythrocyte oxidative stress. *Med Chem* *3*, 289-296.

- Tondury, P., Zimmermann, A., Nielsen, P., and Hirt, A. (1998). Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. *Br J Haematol* *101*, 413-415.
- Vacha, J., Dungal, J., and Kleinwachter, V. (1978). Determination of heme and non-heme iron content of mouse erythropoietic organs. *Exp Hematol* *6*, 718-724.
- Vatanavicharn, S., Anuwatanakulchai, M., Tuntawiroon, M., Suwanik, R., and Wasi, P. (1983). Iron absorption in patients with beta-thalassaemia/haemoglobin E disease and the effect of splenectomy. *Acta haematologica* *69*, 414-416.
- Vichinsky, E., Butensky, E., Fung, E., Hudes, M., Theil, E., Ferrell, L., Williams, R., Louie, L., Lee, P.D., and Harmatz, P. (2005). Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. *Am J journal of Hematol* *80*, 70-74.
- Wallace, K., Burt, A.D., and Wright, M.C. (2008). Liver fibrosis. *Biochem J* *411*, 1-18.
- Wallander, M.L., Leibold, E.A., and Eisenstein, R.S. (2006). Molecular control of vertebrate iron homeostasis by iron regulatory proteins. *Biochim Biophys Acta* *1763*, 668-689.
- Wanless, I.R., Sweeney, G., Dhillon, A.P., Guido, M., Piga, A., Galanello, R., Gamberini, M.R., Schwartz, E., and Cohen, A.R. (2002). Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. *Blood* *100*, 1566-1569.
- Wong, C., and Richardson, D.R. (2003). Beta-thalassaemia: emergence of new and improved iron chelators for treatment. *Int J Biochem Cell Biol* *35*, 1144-1149.
- Wu, S.F., Peng, C.T., Wu, K.H., and Tsai, C.H. (2006). Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. *Hemoglobin* *30*, 215-218.
- Yang, T.T., and Koo, M.W. (2000). Chinese green tea lowers cholesterol level through an increase in fecal lipid excretion. *Life sci* *66*, 411-423.
- Yao, H.T., Huang, S.Y., and Chiang, M.T. (2008). A comparative study on hypoglycemic and hypocholesterolemic effects of high and low molecular weight chitosan in streptozotocin-induced diabetic rats. *Food Chem Toxicol* *46*, 1525-1534.

- Yumei, F., Zhou, Y., Zheng, S., and Chen, A. (2006). The antifibrogenic effect of (-)-epigallocatechin gallate results from the induction of de novo synthesis of glutathione in passaged rat hepatic stellate cells. *Laboratory investigation; J Tech Meth Pathol* 86, 697-709.
- Zaveri, N.T. (2006). Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. *Life Sci* 78, 2073-2080.
- Zhang, A., Zhu, Q.Y., Luk, Y.S., Ho, K.Y., Fung, K.P., and Chen, Z.Y. (1997). Inhibitory effects of jasmine green tea epicatechin isomers on free radical-induced lysis of red blood cells. *Life Sci* 61, 383-394.
- Zheng, G., Sayama, K., Okubo, T., Juneja, L.R., and Oguni, I. (2004). Anti-obesity effects of three major components of green tea, catechins, caffeine and theanine, in mice. *In vivo (Athens, Greece)* 18, 55-62.
- Zhong, Z., Froh, M., Lehnert, M., Schoonhoven, R., Yang, L., Lind, H., Lemasters, J.J., and Thurman, R.G. (2003). Polyphenols from *Camellia sinensis* attenuate experimental cholestasis-induced liver fibrosis in rats. *Am J Physiol* 285, G1004-1013.